CWY0 Stock Overview A clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Clearmind Medicine Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Clearmind Medicine Historical stock prices Current Share Price US$1.10 52 Week High US$2.69 52 Week Low US$0.88 Beta -1.47 1 Month Change -11.19% 3 Month Change 1.85% 1 Year Change -51.19% 3 Year Change -99.68% 5 Year Change n/a Change since IPO -99.80%
Recent News & Updates
Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical Trial Dec 25
Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025 Nov 21
Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy Sep 17 Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment
Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment Aug 22
Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug Aug 07 See more updates
Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical Trial Dec 25
Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025 Nov 21
Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy Sep 17 Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment
Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment Aug 22
Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug Aug 07
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss Jul 16
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product May 11
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders Apr 10
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression Mar 27 Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange Mar 15
Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial Mar 14
Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder Feb 23
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration Feb 06 Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million. Jan 17
Clearmind Medicine Inc. has completed a Follow-on Equity Offering. Jan 16
Clearmind Medicine Inc. has filed a Follow-on Equity Offering. Jan 12 Clearmind Medicine Inc. has filed a Follow-on Equity Offering.
Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards Dec 15
Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial Dec 03
Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial Dec 02
High number of new and inexperienced directors Nov 30
Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment Nov 29
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice Nov 18
Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities Nov 10 Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding Oct 10
Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023 Aug 24
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S Aug 02
Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board Jul 12
Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder May 24
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification May 22
Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder May 13
Clearmind Medicine Inc. Announces Board Appointments May 09
Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office Feb 16
Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound Feb 01
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment Jan 18
Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial Jan 12
Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder Jan 10
Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial Jan 06
Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100 Dec 15
Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial Nov 24
High number of new and inexperienced directors Nov 16
Clearmind Medicine Inc. Common Shares Deleted from OTC Equity Nov 16 Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022 Oct 29
High number of new and inexperienced directors Oct 06 Shareholder Returns CWY0 DE Pharmaceuticals DE Market 7D -2.1% 1.4% 0.5% 1Y -51.2% -16.3% 7.2%
See full shareholder returns
Return vs Market: CWY0 underperformed the German Market which returned 7% over the past year.
Price Volatility Is CWY0's price volatile compared to industry and market? CWY0 volatility CWY0 Average Weekly Movement 10.6% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CWY0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CWY0's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction.
Show more Clearmind Medicine Inc. Fundamentals Summary How do Clearmind Medicine's earnings and revenue compare to its market cap? CWY0 fundamental statistics Market cap €6.08m Earnings (TTM ) -€8.11m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CWY0 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$8.44m Earnings -US$8.44m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 04:13 End of Day Share Price 2024/12/23 00:00 Earnings 2024/07/31 Annual Earnings 2023/10/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Clearmind Medicine Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
